RESUMEN
INTRODUCTION: Drug therapy for Graves' disease (GD) is the first-line treatment in Europe. The use of a specific regimen for the administration of anti-thyroid drugs (ATDs) is still controversial. The objective was to compare block-and-replace therapy (BRT) with a titration (T) regimen in terms of incidence of overt hypothyroidism and development of Graves' orbitopathy (GO) over 18 months of treatment. MATERIAL AND METHODS: Two databases (PubMed, Cochrane Library) and reference lists were searched. Prospective and retrospective observational cohort studies were included. Data collection and analysis were performed independently by 2 authors. RESULTS: Two studies with 716 GD patients (40.36% treated with BRT, 59.64% with T regimen) were included. No statistically significant differences were observed between the ATDs regimens used in terms of incidence of overt hypothyroidism during 18 months of treatment [Mantel-Haenszel (M-H) odds ratio (OR): 1.54, 95% confidence interval (CI): 0.75-3.16, p-value = 0.24]. GD patients who followed BRT were less likely to achieve control of thyroid function than patients on T regimen (M-H OR: 0.55, 95% CI: 0.34-0.88, p = 0.01). One study reported fewer thyroid function tests (TFT) during BRT than during the T regimen. The other study included patients without GO at baseline and reported a lower incidence of GO during BRT than in the T regimen (9.1% versus 17.8%), with no statistical difference between the 2 regimens (M-H OR: 0.47, 95% CI: 0.19-1.14, p = 0.10). CONCLUSION: BRT may be more useful than the T regimen for patients with complicated GD or for those who required fewer TFTs.
Asunto(s)
Antitiroideos , Enfermedad de Graves , Humanos , Antitiroideos/uso terapéutico , Antitiroideos/administración & dosificación , Enfermedad de Graves/tratamiento farmacológico , Femenino , Masculino , Hipotiroidismo/tratamiento farmacológico , Adulto , Persona de Mediana Edad , Oftalmopatía de Graves/tratamiento farmacológico , Resultado del TratamientoRESUMEN
To investigate the effects of levothyroxine combined with methimazole on the clinical efficacy of hyperthyroidism treatment. A total of 102 patients with hyperthyroidism admitted to our hospital from January 2018 to June 2020 were selected and randomly assigned into the combination group (levothyroxine combined with methimazole) and the control group (methimazole treatment alone). 3 months after treatment, the two groups were compared with regard to clinical efficacy, changes in ultrasound findings, the thyroid hormones, and serum indexes and the adverse reactions rate. The combination group (98.04%) outperformed the control group (86.27%) in total effective rate, and the overall efficacy garnered the similar result. After treatment, the combination group showed advantages in thyroid hormone level, serum index level, thyroid volume, superior thyroid artery diameter, and maximum blood flow rate when compared with those of the control group (P<0.05). As for the adverse reactions rate, the combination group was superior to the control group (3.92%vs15.69%) (P<0.05). Levothyroxine combined with methimazole promotes the clinical efficacy of hyperthyroidism treating, reduces thyroid volume and the diameter of superior thyroid artery, enhances the patient's thyroid function and serum index, with higher safety profile.
Asunto(s)
Hipertiroidismo/tratamiento farmacológico , Metimazol/uso terapéutico , Tiroxina/uso terapéutico , Adulto , Anciano , Antitiroideos/administración & dosificación , Antitiroideos/uso terapéutico , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Tiroxina/administración & dosificación , Adulto JovenAsunto(s)
Enfermedad de Graves , Insuficiencia Cardíaca , Hipertensión Pulmonar , Metimazol/administración & dosificación , Propiltiouracilo/administración & dosificación , Síndrome de Cimitarra , Adulto , Antitiroideos/administración & dosificación , Angiografía por Tomografía Computarizada/métodos , Tratamiento Conservador/métodos , Ecocardiografía Transesofágica/métodos , Electrocardiografía/métodos , Femenino , Enfermedad de Graves/complicaciones , Enfermedad de Graves/diagnóstico , Enfermedad de Graves/fisiopatología , Enfermedad de Graves/terapia , Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/etiología , Insuficiencia Cardíaca/fisiopatología , Insuficiencia Cardíaca/terapia , Humanos , Hipertensión Pulmonar/diagnóstico , Hipertensión Pulmonar/etiología , Hipertensión Pulmonar/fisiopatología , Hipertensión Pulmonar/terapia , Procesamiento de Imagen Asistido por Computador/métodos , Síndrome de Cimitarra/complicaciones , Síndrome de Cimitarra/diagnóstico , Síndrome de Cimitarra/fisiopatología , Pruebas de Función de la Tiroides/métodos , Resultado del Tratamiento , Insuficiencia de la Válvula Tricúspide/diagnóstico por imagen , Insuficiencia de la Válvula Tricúspide/etiología , Vena Cava Inferior/diagnóstico por imagenAsunto(s)
Ascitis , Insuficiencia Cardíaca , Hipertiroidismo , Metimazol/administración & dosificación , Metoprolol/administración & dosificación , Dolor Abdominal/diagnóstico , Dolor Abdominal/etiología , Antitiroideos/administración & dosificación , Ascitis/diagnóstico por imagen , Ascitis/etiología , Ascitis/terapia , Fibrilación Atrial/diagnóstico , Diagnóstico Diferencial , Ecocardiografía Transesofágica/métodos , Electrocardiografía/métodos , Femenino , Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/fisiopatología , Insuficiencia Cardíaca/terapia , Humanos , Hipertiroidismo/sangre , Hipertiroidismo/complicaciones , Hipertiroidismo/tratamiento farmacológico , Hipertiroidismo/fisiopatología , Imagen por Resonancia Cinemagnética/métodos , Cumplimiento de la Medicación , Persona de Mediana Edad , Paracentesis/métodos , Pruebas de Función de la Tiroides/métodosRESUMEN
Graves' disease (GD) is an autoimmune disorder that frequently results in hyperthyroidism and other symptoms. Here, we designed a 6-month study with patients divided into three treatment groups, namely, methimazole (MI, n = 8), MI + black bean (n = 9) and MI + probiotic Bifidobacterium longum (n = 9), to evaluate the curative effects of probiotics supplied with MI on thyroid function of patients with GD through clinical index determination and intestinal microbiota metagenomic sequencing. Unsurprisingly, MI intake significantly improved several thyroid indexes but not the most important thyrotropin receptor antibody (TRAb), which is an indicator of the GD recurrence rate. Furthermore, we observed a dramatic response of indigenous microbiota to MI intake, which was reflected in the ecological and evolutionary scale of the intestinal microbiota. In contrast, we did not observe any significant changes in the microbiome in the MI + black bean group. Similarly, the clinical thyroid indexes of patients with GD in the probiotic supplied with MI treatment group continued to improve. Dramatically, the concentration of TRAb recovered to the healthy level. Further mechanistic exploration implied that the consumed probiotic regulated the intestinal microbiota and metabolites. These metabolites impacted neurotransmitter and blood trace elements through the gut-brain axis and gut-thyroid axis, which finally improved the host's thyroid function.
Asunto(s)
Antitiroideos/farmacología , Bifidobacterium longum/química , Enfermedad de Graves/tratamiento farmacológico , Metimazol/farmacología , Probióticos/farmacología , Glándula Tiroides/efectos de los fármacos , Adulto , Antitiroideos/administración & dosificación , Eje Cerebro-Intestino/efectos de los fármacos , Femenino , Humanos , Masculino , Metimazol/administración & dosificación , Persona de Mediana Edad , Probióticos/administración & dosificaciónRESUMEN
Acromegaly is, in most cases, caused by growth hormone secreting pituitary adenomas. Those patients often develop different pathologies of the thyroid gland, however, the occurrence of Grave´s disease is quite a rare situation. We report a case of a 64-year-old female patient who presented with signs of hyperthyroidism and imbalance of her diabetes mellitus. On physical examination, she had facial features of acromegaly. Biochemical testing confirmed the suspicion of acromegaly and Grave´s disease, with an elevated insulin-like growth factor-1 and a suppressed thyroid stimulation hormone (TSH) with positive TSH-receptor antibodies. A pituitary Magnetic Resonance Imaging (MRI) was performed, revealing a macro-adenoma and an empty sella. The patient successfully underwent a transsphenoidal surgery and obtained a remission of her hyperthyroidism under anti-thyroid drugs.
Asunto(s)
Acromegalia/diagnóstico , Síndrome de Silla Turca Vacía/diagnóstico por imagen , Enfermedad de Graves/diagnóstico por imagen , Adenoma Hipofisario Secretor de Hormona del Crecimiento/diagnóstico por imagen , Antitiroideos/administración & dosificación , Diabetes Mellitus/fisiopatología , Femenino , Adenoma Hipofisario Secretor de Hormona del Crecimiento/cirugía , Humanos , Hipertiroidismo/diagnóstico , Hipertiroidismo/tratamiento farmacológico , Factor I del Crecimiento Similar a la Insulina/metabolismo , Imagen por Resonancia Magnética , Persona de Mediana Edad , Tirotropina/metabolismoRESUMEN
Dipeptidyl peptidase-4 (DPP-4), namely CD26, is expressed on the surface of immune cells, suggesting that inhibition of DPP-4 might affect the immune system. The current multicenter observational case-control study was carried out to investigate the effects of DPP-4 inhibitor (DPP-4i) administration on Graves' disease (GD) activity. This study comprised patients with GD and type 2 diabetes, who were administered an oral hypoglycemic agent including DPP-4i. Exacerbation of GD was defined as an increase of antithyroid drug dose by 6 months after oral hypoglycemic agent administration. A total of 80 patients were enrolled and divided into an exacerbation group or a non-exacerbation group. The frequency of DPP-4i administration was significantly higher in the exacerbation group (88%) than that in the non-exacerbation group (31%). In multivariate logistic regression analysis, there was a significant association between DPP-4i administration and GD exacerbation (odds ratio 7.39). The current study suggests that DPP-4i administration is associated with GD exacerbation.
Asunto(s)
Antitiroideos/administración & dosificación , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Inhibidores de la Dipeptidil-Peptidasa IV/efectos adversos , Enfermedad de Graves/inmunología , Hipoglucemiantes/efectos adversos , Anciano , Estudios de Casos y Controles , Diabetes Mellitus Tipo 2/inmunología , Dipeptidil Peptidasa 4/efectos de los fármacos , Dipeptidil Peptidasa 4/inmunología , Inhibidores de la Dipeptidil-Peptidasa IV/inmunología , Progresión de la Enfermedad , Femenino , Enfermedad de Graves/tratamiento farmacológico , Humanos , Hipoglucemiantes/inmunología , Modelos Logísticos , Masculino , Persona de Mediana Edad , Oportunidad RelativaRESUMEN
Brain-body interactions are thought to be essential in emotions but their physiological basis remains poorly understood. In mice, regular 4 Hz breathing appears during freezing after cue-fear conditioning. Here we show that the olfactory bulb (OB) transmits this rhythm to the dorsomedial prefrontal cortex (dmPFC) where it organizes neural activity. Reduction of the respiratory-related 4 Hz oscillation, via bulbectomy or optogenetic perturbation of the OB, reduces freezing. Behavioural modelling shows that this is due to a specific reduction in freezing maintenance without impacting its initiation, thus dissociating these two phenomena. dmPFC LFP and firing patterns support the region's specific function in freezing maintenance. In particular, population analysis reveals that network activity tracks 4 Hz power dynamics during freezing and reaches a stable state at 4 Hz peak that lasts until freezing termination. These results provide a potential mechanism and a functional role for bodily feedback in emotions and therefore shed light on the historical James-Cannon debate.
Asunto(s)
Miedo/fisiología , Bulbo Olfatorio/fisiología , Corteza Prefrontal/fisiología , Respiración , Potenciales de Acción/fisiología , Animales , Antitiroideos/administración & dosificación , Antitiroideos/farmacología , Electrofisiología , Interneuronas/citología , Interneuronas/fisiología , Masculino , Cadenas de Markov , Metimazol/administración & dosificación , Metimazol/farmacología , Ratones , Ratones Endogámicos C57BL , Modelos Psicológicos , Optogenética , Periodicidad , Células Piramidales/citología , Células Piramidales/fisiología , Respiración/efectos de los fármacosRESUMEN
Antithyroid drugs (ATDs) are the mainstay of treatment for Graves' disease with possible detrimental adverse effects. Surgery or radioactive iodine (RAI) ablation is the second choice among the treatment options in cases of non-remission. Normalization of serum thyroid hormone levels as much as possible is required before surgery or RAI to prevent thyrotoxic crisis in patients with uncontrolled Graves' disease. In recent decades, therapeutic plasma exchange (TPE) has been used in the treatment of thyroid storm, drug-induced hepatotoxicity and agranulocytosis, or patients with hyperthyroidism scheduled for emergency surgery. TPE is an effective method to reduce serum FT3, FT4, and TRAB levels in severe hyperthyroid conditions. Although TPE-related complications are rare, the risk of bleeding needs to be taken into consideration in patients who were scheduled for surgery within 24 h after TPE. In terms of reducing intraoperative bleeding, patients can be referred to surgery 24-48 h after TPE, or fresh frozen plasma transfusion can be the preferred treatment for emergency cases.
Asunto(s)
Antitiroideos/administración & dosificación , Enfermedad de Graves/terapia , Plasmaféresis/métodos , Cuidados Preoperatorios/métodos , Enfermedad de Graves/cirugía , HumanosRESUMEN
Background: Population studies on the prevalence of thyroid dysfunctions are costly. The pharmacy dispensing (PDR) and diagnosis (DR) registers allow us to study the epidemiology of these pathologies in a simpler way. Our aims: 1/Estimate the prevalence of thyroid dysfunction in Catalonia based on data from the PDR and the DR, 2/to evaluate the concordance of the results obtained by both strategies. Methods: The population studied was the one registered with the public health system in Catalonia(Catsalut). In the PDR analysis, the information obtained through the Pharmaceutical Provision file (during 2012, 2013, 2014) was used regarding the number of patients under treatment (NPT) (levothyroxine and antithyroid medication). The DR analysis (2014) was performed by ICD-9 codes (hyperthyroidism 242 and hypothyroidism 243, 244). Results: According to the NPT in the PDR analysis, the prevalence of treated hypothyroidism increased over 3 years: 2.81%(2012), 2.92%(2013) and 3.07%(2014) (P < .00001). The prevalence of hyperthyroidism in treatment was 0.14%(2012), 0.13%(2013) and 0.14%(2014). According to the DR analysis in 2014, the prevalence of hypothyroidism was 2.54% and 0.35% for hyperthyroidism. The PDR analysis estimated a higher hypothyroidism prevalence compared to that estimated by the DR (P < .0001) and vice versa in the case of hyperthyroidism. Conclusion: Both PDR and DR prevalence estimations of thyroid dysfunction show some degree of discordance probably due to undercoding bias in the case of DR and the absence of subclinical pathology in the case of PDR. However, both approaches are valid and complementary for estimating the prevalence of thyroid dysfunction.
Asunto(s)
Prescripciones de Medicamentos/estadística & datos numéricos , Hipertiroidismo/tratamiento farmacológico , Hipertiroidismo/epidemiología , Hipotiroidismo/tratamiento farmacológico , Hipotiroidismo/epidemiología , Sistema de Registros , Adolescente , Adulto , Anciano , Antitiroideos/administración & dosificación , Femenino , Humanos , Hipertiroidismo/fisiopatología , Hipotiroidismo/fisiopatología , Masculino , Persona de Mediana Edad , Farmacoepidemiología , Prevalencia , España/epidemiología , Glándula Tiroides/fisiopatología , Tiroxina/administración & dosificación , Adulto JovenRESUMEN
Background: Several studies have investigated the factors affecting the effects of radioactive iodine (131I) treatment (RAIT) in patients with Graves' disease. However, the influence of dietary or therapeutic iodine on the effect of RAIT has not been fully elucidated yet. The aim of this study was to investigate whether dietary or therapeutic iodine before RAIT influences the therapeutic effects of RAIT with a fixed-dose regimen and a short-term restriction of iodine intake in an iodine-sufficient area. Materials and Methods: We retrospectively analyzed 81 Japanese patients with Graves' disease treated with the following RAIT regimen: dietary iodine restriction for 7 days as well as discontinuation of antithyroid drugs (ATDs), potassium iodine (KI), or both for 5 days before RAIT. On the day of RAIT, we measured urinary iodine content to estimate daily iodine intake. After RAIT, we adjusted the dose of ATDs, KI, or both according to serum thyroid hormone levels every 1-2 months. Using the data from these patients, we investigated the effect of dietary and therapeutic iodine on the therapeutic effects of RAIT. The therapeutic effects at 1 year after RAIT were evaluated based on the necessity of ATDs, KI, or both. Results: Dietary iodine intake was weakly correlated with 131I uptake (RAIU), but the dose of therapeutic iodine was not correlated with RAIU. The therapeutic effects of RAIT were strongly negatively associated with estimated thyroid volume before RAIT. Neither dietary iodine intake nor therapeutic iodine before RAIT affected this association. Conclusion: This study did not find an association between short-term dietary or therapeutic iodine restriction before RAIT and the therapeutic effects of RAIT in an iodine-sufficient area.
Asunto(s)
Enfermedad de Graves/radioterapia , Radioisótopos de Yodo/uso terapéutico , Radiofármacos/uso terapéutico , Adulto , Antitiroideos/administración & dosificación , Antitiroideos/efectos adversos , Dieta/efectos adversos , Esquema de Medicación , Femenino , Enfermedad de Graves/diagnóstico , Humanos , Radioisótopos de Yodo/efectos adversos , Masculino , Persona de Mediana Edad , Yoduro de Potasio/administración & dosificación , Yoduro de Potasio/efectos adversos , Radiofármacos/efectos adversos , Estudios Retrospectivos , Factores de Riesgo , Factores de Tiempo , Tokio , Resultado del TratamientoRESUMEN
PURPOSE: Whereas antithyroid drugs (ATD) are the preferred treatment modality for Graves' hyperthyroidism (GH), there is still controversy about the optimal regimen for delivering ATD. To evaluate whether 'Block and Replace' (B + R) and 'Titration' (T) regimes are equivalent in terms of frequency of euthyroidism and Graves' Orbitopathy (GO) during ATD therapy. METHODS: A prospective multicentre observational cohort study of 344 patients with GH but no GO at baseline. Patients were treated with ATD for 18 months according to B + R or T regimen in line with their institution's policy. RESULTS: Baseline characteristics were similar in both groups. In the treatment period between 6 and 18 months thyrotropin (TSH) slightly increased in both groups, but TSH was on average 0.59 mU/L (95% CI 0.27-0.85) lower in the B + R group at all time points (p = 0.026). Serum free thyroxine (FT4) remained stable during the same interval, with a tendency to higher values in the B + R group. The point-prevalence of euthyroidism (TSH and FT4 within their reference ranges) increased with longer duration of ATD in both groups; it was always higher in the T group than in the B + R group: 48 and 24%, respectively, at 6 months, 81 and 58% at 12 months, and 87 and 63% at 18 months (p < 0.002). There were no significant differences between the B + R and T regimens with respect to the fall in thyrotropin binding inhibiting immunoglobulins (TBII) or thyroid peroxidase antibodies (TPO-Ab). GO developed in 15.9% of all patients: 9.1 and 17.8% in B + R group and T group, respectively, (p = 0.096). GO was mild in 13% and moderate-to-severe in 2%. CONCLUSION: The prevalence of biochemical euthyroidism during treatment with antithyroid drugs is higher during T compared to B + R regimen. De novo development of GO did not differ significantly between the two regimens, although it tended to be higher in the T group. Whether one regimen is clinically more advantageous than the other remains unclear.
Asunto(s)
Antitiroideos/administración & dosificación , Enfermedad de Graves/tratamiento farmacológico , Oftalmopatía de Graves/patología , Hipertiroidismo/tratamiento farmacológico , Hormonas Tiroideas/metabolismo , Adulto , Antitiroideos/efectos adversos , Europa (Continente)/epidemiología , Femenino , Estudios de Seguimiento , Oftalmopatía de Graves/inducido químicamente , Oftalmopatía de Graves/epidemiología , Oftalmopatía de Graves/metabolismo , Humanos , Masculino , Pronóstico , Estudios Prospectivos , Pruebas de Función de la Tiroides , Factores de TiempoRESUMEN
BACKGROUND: Immune checkpoint blockade therapy may lead to thyroid dysfunction in 3-7% of treated patients. Alemtuzumab is a CD52 inhibitor leading to thyroid dysfunction in approximately 40% of patients. A female patient was affected by multiple sclerosis (MS) and subclinical hyperthyroidism due to an autonomously functioning thyroid nodule (AFTN). After alemtuzumab treatment, she developed aggressive clinical hyperthyroidism consistent with Marine-Lenhart syndrome. CASE PRESENTATION: A 36-year-old woman presented in July 2019 with symptoms of hyperthyroidism and eye complaints. Three years earlier, she was diagnosed with MS. Subclinical hyperthyroidism was diagnosed in April 2017. Thyroid scintigraphy showed an intranodular distribution of 99mTc-pertechnatate consisting of an AFTN in the right lobe of the thyroid. In June 2018, because of the MS, she was treated with alemtuzumab. In November 2018, she was started on methimazole treatment because of the symptoms of hyperthyroidism. In December 2018, thyroid function was normal under methimazole treatment. In June 2019, the patient received a second round of alemtuzumab administration. One month later, she developed symptoms of hyperthyroidism. These symptoms were accompanied by diplopia. Blood tests showed severe hyperthyroidism. Thyroid scintigraphy showed a diffuse distribution of 99mTc-pertechnatate and the presence of a "cool" area in the right lobe of the thyroid, confirmed by ultrasonography. The nodule was diagnosed as a low-risk indeterminate lesion. CONCLUSION: We present a case of Graves' disease with active, moderate-to-severe Graves' ophthalmopathy in a patient with pre-existing AFTN presenting with a coexisting, rare case of Marine-Lenhart syndrome associated with immune reconstitution after alemtuzumab treatment.
Asunto(s)
Alemtuzumab/efectos adversos , Alemtuzumab/uso terapéutico , Enfermedad de Graves/complicaciones , Oftalmopatía de Graves/inducido químicamente , Esclerosis Múltiple/tratamiento farmacológico , Adulto , Antineoplásicos Inmunológicos/efectos adversos , Antineoplásicos Inmunológicos/uso terapéutico , Antitiroideos/administración & dosificación , Antitiroideos/uso terapéutico , Femenino , Oftalmopatía de Graves/patología , Humanos , Metimazol/administración & dosificación , Metimazol/uso terapéutico , Metionina/administración & dosificación , Metionina/análogos & derivados , Metionina/uso terapéutico , Compuestos de Organoselenio/administración & dosificación , Compuestos de Organoselenio/uso terapéuticoRESUMEN
INTRODUCTION: Hashimoto's Thyroiditis (HT) is one of the common autoimmune diseases, which can lead to thyroid reduction, increase the risk of tumor, and seriously affect women's reproductive health. Many other autoimmune diseases are easy to occur, seriously harming people's health.large dose herb Prunella or compound prescription contain large dose Prunella for treatment of HT has already been confirmed. However, due to the lack of evidence, there is no specific method or suggestion, it is necessary to carry out a systematic evaluation on Prunella and provide effective evidence for further research. METHODS AND ANALYSIS: The following databases will be searched from their inception to October 2020: Electronic database includes PubMed, Embase, Cochrane Library, Web of Science, Nature, Science online, Chinese Biomedical Database WangFang, VIP medicine information, and China National Knowledge Infrastructure. MAIN RESULTS: serum thyroid peroxidase antibody (TPOAb), thyroid globulin antibody (TGAb), other results: serum thyroid stimulating hormone (TSH), serum free triiodothyronine (FT3), serum free thyroid hormone (FT4). Data will be extracted by 2 researchers independently, risk of bias of the meta-analysis will be evaluated based on the Cochrane Handbook for Systematic Reviews (SR)of Interventions. All data analysis will be conducted by data statistics software Review Manager V.5.3. and Stata V.12.0. RESULTS: The results of this study will systematically evaluate the efficacy and safety of large dose prunella salicorrhizae in the intervention of people with HT. CONCLUSION: The systematic review of this study will summarize the current published evidence of large dose prunella for the treatment of HT, which can further guide the promotion and application of it. ETHICS AND COMMUNICATION: This study is a systematic review, the outcomes are based on the published evidence, so examination and agreement by the ethics committee are not required in this study. We intend to publish the study results in a journal or conference presentations.Open Science Fra mework (OSF) registration number:October 21, 2020.osf.io/fcyqp. (https://osf.io/fcyqp).
Asunto(s)
Antitiroideos/administración & dosificación , Medicamentos Herbarios Chinos/administración & dosificación , Enfermedad de Hashimoto/tratamiento farmacológico , Prunella , Adulto , Relación Dosis-Respuesta a Droga , Femenino , Enfermedad de Hashimoto/sangre , Humanos , Metaanálisis como Asunto , Ensayos Clínicos Controlados Aleatorios como Asunto , Proyectos de Investigación , Revisiones Sistemáticas como Asunto , Pruebas de Función de la Tiroides , Hormonas Tiroideas/sangre , Resultado del TratamientoRESUMEN
OBJECTIVE: First-line treatment of thyrotoxicosis in young people is thionamide anti-thyroid drug (ATD) in a blocking dose with levothyroxine replacement (block and replace, BR) or in a smaller dose tailored to render the patient euthyroid (dose titration, DT). Our objective was to determine which regimen provides more stable biochemical control. DESIGN: A multi-centre phase III, open-label randomised trial comparing BR with DT in patients aged 2-17 years with newly diagnosed thyrotoxicosis at 15 UK centres. METHODS: Patients were randomised shortly after diagnosis and treated for 3 years. The primary outcome was the percentage of serum thyroid-stimulating hormone (TSH) levels in the reference range between 6 months and 3 years. Secondary outcomes included the proportion of Free thyroxine (FT4) levels in the reference range, adverse event frequency and 4 years outcome (remission/relapse). RESULTS: Eighty-two patients were randomised, with details on clinical course in 81 (62 Female); 40 were allocated to BR (41 DT). Three withdrew with one ineligible. The mean percentage of serum TSH within reference range was 60.2% in BR and 63.8% in DT patients; adjusted difference 4.3%, 95% CI (-7.8 to 16.4); P = 0.48. Proportions for FT4 were 79.2% in BR and 85.7% in DT patients; adjusted difference 6.8%, (-0.2 to 15.6); P = 0.13. Three patients developed neutropenia - all on BR. 6 BR and 10 DT patients were in remission at 4y. CONCLUSION: This randomised trial has shown no evidence to suggest that BR, when managing the young patient with thyrotoxicosis, is associated with improved biochemical stability when compared to DT.
Asunto(s)
Antitiroideos/administración & dosificación , Terapia de Reemplazo de Hormonas/métodos , Tirotoxicosis/tratamiento farmacológico , Tiroxina/administración & dosificación , Adolescente , Niño , Preescolar , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Masculino , Valores de Referencia , Tirotoxicosis/sangre , Tirotropina/sangre , Resultado del TratamientoRESUMEN
Elevated serum creatine kinase (CK) concentration was reported in some Graves disease patients during the treatment with oral antithyroid drugs (ATD). The pathogenesis of this abnormal biochemical value was considered to be related to the therapeutic drug. However, the relevant epidemiological investigation was absent.Overall, 416 patients with Graves disease treated with oral ATDs were recruited from December 2017 to October 2019. Clinical characteristics such as the patient's medical history and therapeutic regimen were collected. Serum CK concentration and thyroid function were measured. Statistical analysis was adopted to clarify the relationship between serum CK level and these clinical parameters.Elevation of serum CK concentration was emerged in 13.5% patients who were treated with oral ATDs. The proportion was significantly higher among men than among women (19.5% vs 10.8%). There was no correlation between increased serum CK concentration and age. More than 60% of serum CK elevations occurred within 6 months after taking oral ATDs. Free triiodothyronine and free thyroxine are negatively correlated with serum CK concentration. The correlation coefficients are respectively -0.222 (Pâ<â.05) and -0.234 (Pâ<â.05). There is positive correlation between thyroid stimulating hormone and serum CK concentration. The correlation coefficient is 0.405 (Pâ<â.05). There was no statistical correlation between drug dosage and increased serum CK level.Increased serum CK level is a common adverse reaction of oral ATDs. It generally develops early after starting treatment. The cause of this adverse reaction is not clear. It is speculated that elevation of serum CK level is related to the fluctuation of thyroid function.
Asunto(s)
Antitiroideos/efectos adversos , Antitiroideos/uso terapéutico , Creatina Quinasa/sangre , Enfermedad de Graves/tratamiento farmacológico , Administración Oral , Adolescente , Adulto , Anciano , Antitiroideos/administración & dosificación , Estudios de Casos y Controles , Niño , China/epidemiología , Creatina Quinasa/efectos de los fármacos , Estudios Transversales , Femenino , Enfermedad de Graves/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Pruebas de Función de la Tiroides/métodos , Tirotropina/sangre , Tiroxina/sangre , Triyodotironina/sangre , Adulto JovenRESUMEN
Plant-based diets are associated with reduced risk of lifestyle-induced chronic diseases. The thousands of phytochemicals they contain are implicated in cellular-based mechanisms to promote antioxidant defense and reduce inflammation. While recommendations encourage the intake of fruits and vegetables, most people fall short of their target daily intake. Despite the need to increase plant-food consumption, there have been some concerns raised about whether they are beneficial because of the various 'anti-nutrient' compounds they contain. Some of these anti-nutrients that have been called into question included lectins, oxalates, goitrogens, phytoestrogens, phytates, and tannins. As a result, there may be select individuals with specific health conditions who elect to decrease their plant food intake despite potential benefits. The purpose of this narrative review is to examine the science of these 'anti-nutrients' and weigh the evidence of whether these compounds pose an actual health threat.
Asunto(s)
Dieta Vegetariana , Nutrientes , Fitoquímicos/administración & dosificación , Fitoquímicos/efectos adversos , Antioxidantes/administración & dosificación , Antioxidantes/efectos adversos , Antioxidantes/análisis , Antitiroideos/administración & dosificación , Antitiroideos/efectos adversos , Antitiroideos/análisis , Culinaria , Manipulación de Alimentos , Frutas/química , Humanos , Lectinas/administración & dosificación , Lectinas/efectos adversos , Lectinas/análisis , Oxalatos/administración & dosificación , Oxalatos/efectos adversos , Oxalatos/análisis , Ácido Fítico/administración & dosificación , Ácido Fítico/efectos adversos , Ácido Fítico/análisis , Fitoquímicos/análisis , Fitoestrógenos/administración & dosificación , Fitoestrógenos/efectos adversos , Fitoestrógenos/análisis , Taninos/administración & dosificación , Taninos/efectos adversos , Taninos/análisis , Verduras/químicaAsunto(s)
Infecciones por Coronavirus , Enfermedad de Graves , Metimazol/administración & dosificación , Pandemias , Neumonía Viral , Propranolol/administración & dosificación , Receptores de Tirotropina/inmunología , Tiroglobulina/inmunología , Antagonistas Adrenérgicos beta/administración & dosificación , Anticuerpos/sangre , Antitiroideos/administración & dosificación , Betacoronavirus/aislamiento & purificación , COVID-19 , Prueba de COVID-19 , Técnicas de Laboratorio Clínico/métodos , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/inmunología , Infecciones por Coronavirus/fisiopatología , Femenino , Enfermedad de Graves/sangre , Enfermedad de Graves/etiología , Enfermedad de Graves/fisiopatología , Enfermedad de Graves/terapia , Humanos , Pulmón/diagnóstico por imagen , Persona de Mediana Edad , Neumonía Viral/complicaciones , Neumonía Viral/diagnóstico , Neumonía Viral/etiología , Neumonía Viral/inmunología , Neumonía Viral/fisiopatología , SARS-CoV-2 , Pruebas de Función de la Tiroides/métodos , Resultado del Tratamiento , Ultrasonografía/métodosRESUMEN
Background: A course of anti-thyroid drugs (ATD) is the most common first line treatment for Graves' hyperthyroidism. However, hyperthyroidism relapse is frequent (30-70%). Due to the autoimmune nature of Graves' disease, the immunosuppressive treatment used for active Graves' orbitopathy (GO) may reduce the relapses after ATD discontinuation. Objective: To evaluate the recurrence rate in Graves' patients who, in addition to standard ATD, were treated or not treated with parenteral methylprednisolone (MPDS) for GO. Methods: Single-center retrospective study in a continuous series of 162 newly diagnosed Graves' patients, with or without GO, all gone into remission and followed-up until hyperthyroidism recurrence or at least 4 years after ATD discontinuation. Patients with moderate-severe active GO underwent middle dose MPDS treatment according to the EuGoGo guidelines. Cox proportional-hazard model was used to comparatively evaluate the risk of recurrence and the predictive factors in patients treated or not treated with MPDS pulse therapy. Results: MPDS treatment was the most significant factor that independently correlated with a reduced risk of hyperthyroidism relapse (HR = 0.53, 95% C.I. = 0.31-0.89). FT3 and female sex were also independent protective factors, while age almost reached the significance level, p = 0.062. The efficacy of MPDS was very high in patients aged <40 years (42.1% decrease in relapses, p < 0.01) but it was not significant in older patients. Discussion: Our study found that after ATD discontinuation the frequency of Graves' hyperthyroidism relapse was reduced in patients treated with MPDS pulse therapy for GO. This effect was more marked in young patients.
Asunto(s)
Corticoesteroides/administración & dosificación , Antitiroideos/administración & dosificación , Enfermedad de Graves/tratamiento farmacológico , Enfermedad de Graves/epidemiología , Oftalmopatía de Graves/tratamiento farmacológico , Oftalmopatía de Graves/epidemiología , Metilprednisolona/administración & dosificación , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recurrencia , Prevención Secundaria , Resultado del TratamientoRESUMEN
BACKGROUND: Mechanical ventilation (MV) is life saving; yet it may induce severe lung injury and lead to multisystem organ failure and death. Thyroid hormones (THs) promote alveolar fluid clearance and alleviates hypoxia-induced lung injury. Given that the mechanism involved in hypoxia-induced lung injury is different from that of ventilator-induced lung injury, we examined the effects of thyroid function on lung extravascular fluid (LF), aquaporin 5 (AQP 5) expression, and alveolar viscoelasticity (AVE) in mechanically ventilated rat. METHODS: Hypothyroid (hypo) and hyperthyroid (hyper) animals were generated by administration of metimazole and L-thyroxine, respectively. Lung injury was induced by high-tidal volume MV. The LF was estimated by lung wet weight-to-dry weight ratio assessment. Expression of AQP 5 was evaluated by western blotting and in situ immunohistochemistry. The AVE was judged by elastic lung pressure/volume curve recording. RESULTS: Injurious MV significantly reduced lung AQP 5 expression and altered LF and AVE in a thyroid function-dependent manner. Regardless of animals' ventilation mode, hyper state caused significant reductions in LF and lung AQP 5 protein. It also improved AVE irrespective of animals' ventilation mode. The effects of hypo condition on LF, AQP 5 expression, and AVE were in contrast to that of hyper state. CONCLUSIONS: These data indicate that thyroid function has profound effects on LF, AQP 5, and AVE in mechanically ventilated lungs. Given that the effects of thyroidal status were as prominent as that of injurious MV, we suggest that thyroid function should be considered when patients are to be subjected to MV.